

# Functional coordination of non-myocytes plays a key role in adult zebrafish heart regeneration

Hong Ma, Ziqing Liu, Yuchen Yang, Dong Feng, Yanhan Dong, Tiffany Garbutt, Zhiyuan Hu, Li Wang, Changfei Luan, Cynthia Cooper, Yun Li, Joshua Welch, Li Qian, and Jiandong Liu

DOI: [10.15252/embr.202152901](https://doi.org/10.15252/embr.202152901)

Corresponding author(s): Jiandong Liu ([jiandong\\_liu@med.unc.edu](mailto:jiandong_liu@med.unc.edu)), Li Qian ([li\\_qian@med.unc.edu](mailto:li_qian@med.unc.edu)), Joshua Welch ([welchjd@umich.edu](mailto:welchjd@umich.edu))

---

## Review Timeline:

|                     |             |
|---------------------|-------------|
| Submission Date:    | 19th Mar 21 |
| Editorial Decision: | 15th Apr 21 |
| Revision Received:  | 27th Apr 21 |
| Editorial Decision: | 7th Jul 21  |
| Revision Received:  | 7th Jul 21  |
| Accepted:           | 13th Aug 21 |

---

Editor: Martina Rembold

**Transaction Report: This manuscript was transferred to EMBO reports following peer review at The EMBO Journal.**

No Peer Review Process File is available with this article, as the authors have chosen not to make the review process public.

**YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND** ↓

PLEASE NOTE THAT THIS CHECKLIST WILL BE PUBLISHED ALONGSIDE YOUR PAPER

Corresponding Author Name: Jiandong Liu

Journal Submitted to: EMBO Journal

Manuscript Number: EMBOJ-2020-105922

### Reporting Checklist For Life Sciences Articles (Rev. June 2017)

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.

#### A- Figures

##### 1. Data

The data shown in figures should satisfy the following conditions:

- the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner.
- figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way.
- graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates.
- if  $n < 5$ , the individual data points from each experiment should be plotted and any statistical test employed should be justified.
- Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.

##### 2. Captions

Each figure caption should contain the following information, for each panel where they are relevant:

- a specification of the experimental system investigated (eg cell line, species name).
- the assay(s) and method(s) used to carry out the reported observations and measurements
- an explicit mention of the biological and chemical entity(ies) that are being measured.
- an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
- the exact sample size (n) for each experimental group/condition, given as a number, not a range;
- a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
- a statement of how many times the experiment shown was independently replicated in the laboratory.
- definitions of statistical methods and measures:
  - common tests, such as t-test (please specify whether paired vs. unpaired), simple  $\chi^2$  tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section;
  - are tests one-sided or two-sided?
  - are there adjustments for multiple comparisons?
  - exact statistical test results, e.g., P values = x but not P values < x;
  - definition of 'center values' as median or average;
  - definition of error bars as s.d. or s.e.m.

Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.

In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.

#### B- Statistics and general methods

Please fill out these boxes ↓ (Do not worry if you cannot see all your text once you press return)

|   |   |
|---|---|
| 1.a. How was the sample size chosen to ensure adequate power to detect a pre-specified effect size?   | Based on the general principle in the field, at least 3 biological repeats were applied in the assays. In detail, for qPCR, at least 3 independent samples were used; For ICC, 5 hearts were used for the quantification; For CM proliferation index, 10 hearts for each group were used.   |
| 1.b. For animal studies, include a statement about sample size estimate even if no statistical methods were used.   | We labelled the sample size in the figure legends.  |
| 2. Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre-established?  | For scRNA-seq analysis, low-quality cells expressing $\leq 200$ unique genes were filtered out. Cells expressing high levels of ckma, tnnt2 and nppa were identified as residual cardiomyocytes and removed. Furthermore, clusters expressing high levels of canonical markers of any two of non-cardiomyocyte cell types were considered as doublets and also excluded from further analyses. The observed frequencies of doublets were consistent with the expected frequencies of the two nonCM cell types involved. |
| 3. Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. randomization procedure)? If yes, please describe.                | In order to minimize the subjective bias, 2 persons performed the animal procedure at the same time. The animals were randomized into groups, which were blind to the surgeon. All the sections were labelled with number and blind to the histologists. It was also indicated in the method part.  |
| For animal studies, include a statement about randomization even if no randomization was used.  | The randomization was indicated in the method part.   |
| 4.a. Were any steps taken to minimize the effects of subjective bias during group allocation or/and when assessing results (e.g. blinding of the investigator)? If yes please describe. | Yes. LIGER/0.3.1 was employed for integrative analysis across multiple scRNA-seq datasets, in order to remove the batch effect/technical bias among batches.  |
| 4.b. For animal studies, include a statement about blinding even if no blinding was done  | The blinding was indicated in the method part.  |
| 5. For every figure, are statistical tests justified as appropriate?  | Yes   |
| Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.  | Yes. Non-parametric test Wilcoxon test was employed to examine the strength of transition from MC2 to MC1 across different time points.   |

#### USEFUL LINKS FOR COMPLETING THIS FORM

<http://www.antibodypedia.com>  
<http://1degreebio.org>  
<http://www.equator-network.org/reporting-guidelines/improving-bioscience-research-repor>  
  
<http://grants.nih.gov/grants/olaw/olaw.htm>  
<http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Useofanimals/index.htm>  
<http://ClinicalTrials.gov>  
<http://www.consort-statement.org>  
<http://www.consort-statement.org/checklists/view/32-consort/66-title>  
  
<http://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tum>  
  
<http://datadryad.org>  
  
<http://figshare.com>  
  
<http://www.ncbi.nlm.nih.gov/gap>  
  
<http://www.ebi.ac.uk/ega>  
  
<http://biomodels.net/>  
  
<http://biomodels.net/miriam/>  
<http://jij.biochem.sun.ac.za>  
[http://oba.od.nih.gov/biosecurity/biosecurity\\_documents.html](http://oba.od.nih.gov/biosecurity/biosecurity_documents.html)  
<http://www.selectagents.gov/>

|   |     |
|---|-----|
| Is there an estimate of variation within each group of data?                      | Yes |
| Is the variance similar between the groups that are being statistically compared? | Yes |

### C- Reagents

|  |  |
|--|--|
| 6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia ( <a href="#">see link list at top right</a> ), 1DegreeBio ( <a href="#">see link list at top right</a> ). | The antibodies used in the histology were labelled with catalog number in the method part ("Histology"). |
| 7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.  | NA   |

\* for all hyperlinks, please see the table at the top right of the document

### D- Animal Models

|  |  |
|--|--|
| 8. Report species, strain, gender, age of animals and genetic modification status where applicable. Please detail housing and husbandry conditions and the source of animals.  | The fish lines applied in the current study was indicated in the method part ("Zebrafish Strain"). |
| 9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.   | The detail was provided in the method part ("Zebrafish Strain").                                   |
| 10. We recommend consulting the ARRIVE guidelines ( <a href="#">see link list at top right</a> ) (PLoS Biol. 8(6), e1000412, 2010) to ensure that other relevant aspects of animal studies are adequately reported. See author guidelines, under 'Reporting Guidelines'. See also: NIH ( <a href="#">see link list at top right</a> ) and MRC ( <a href="#">see link list at top right</a> ) recommendations. Please confirm compliance. | Yes  |

### E- Human Subjects

|  |    |
|--|----|
| 11. Identify the committee(s) approving the study protocol.  | NA |
| 12. Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.  | NA |
| 13. For publication of patient photos, include a statement confirming that consent to publish was obtained.  | NA |
| 14. Report any restrictions on the availability (and/or on the use) of human data or samples.  | NA |
| 15. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent), where applicable.   | NA |
| 16. For phase II and III randomized controlled trials, please refer to the CONSORT flow diagram ( <a href="#">see link list at top right</a> ) and submit the CONSORT checklist ( <a href="#">see link list at top right</a> ) with your submission. See author guidelines, under 'Reporting Guidelines'. Please confirm you have submitted this list. | NA |
| 17. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines ( <a href="#">see link list at top right</a> ). See author guidelines, under 'Reporting Guidelines'. Please confirm you have followed these guidelines.  | NA |

### F- Data Accessibility

|  |   |
|--|---|
| 18. Provide a "Data Availability" section at the end of the Materials & Methods, listing the accession codes for data generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462, Proteomics data: PRIDE PXD000208 etc.) Please refer to our author guidelines for 'Data Deposition'.<br><br>Data deposition in a public repository is mandatory for:<br>a. Protein, DNA and RNA sequences<br>b. Macromolecular structures<br>c. Crystallographic data for small molecules<br>d. Functional genomics data<br>e. Proteomics and molecular interactions   | We have added a "Data Availability" section at the end of the Materials and Methods, which lists the GEO accession number of the RNA-seq data we generated in this study.   |
| 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad ( <a href="#">see link list at top right</a> ) or Figshare ( <a href="#">see link list at top right</a> )).  | The RNA-sequencing data we generated in this study are deposited in GEO under accession number GSE145982.   |
| 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-controlled repositories such as dbGAP ( <a href="#">see link list at top right</a> ) or EGA ( <a href="#">see link list at top right</a> ).  | NA  |
| 21. Computational models that are central and integral to a study should be shared without restrictions and provided in a machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized format (SBML, CellML) should be used instead of scripts (e.g. MATLAB). Authors are strongly encouraged to follow the MIRIAM guidelines ( <a href="#">see link list at top right</a> ) and deposit their model in a public database such as Biomedels ( <a href="#">see link list at top right</a> ) or JWS Online ( <a href="#">see link list at top right</a> ). If computer source code is provided with the paper, it should be deposited in a public repository or included in supplementary information. | The novel approach, Topologizer, we developed in this study has been released in the public repository of GitHub ( <a href="https://github.com/welch-lab/topologizer">https://github.com/welch-lab/topologizer</a> ) for public free use. |

### G- Dual use research of concern

|   |    |
|---|----|
| 22. Could your study fall under dual use research restrictions? Please check biosecurity documents ( <a href="#">see link list at top right</a> ) and list of select agents and toxins (APHIS/CDC) ( <a href="#">see link list at top right</a> ). According to our biosecurity guidelines, provide a statement only if it could. | NA |
|---|----|